CoChat

Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer

Rieder, Simon, W. Michalski, Christoph, Friess, Helmut, Kleeff, > · 2011 · Anti-Cancer Agents in Medicinal Chemistry

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

Insulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In pancreatic cancer, IGF-1 and its receptor are constitutively overexpressed. Mammalian target of rapamycin (mTOR) is the main mediator of mitogenic stimuli transduced by PI3K/Akt. Interestingly, inhibition of mTOR activates PI3K/Akt by up-regulating IGF-1R signaling. Several targeted agents have been developed to inhibit the activity of IGF-1 or to block IGF-1R. These pharmaceuticals may offer additional ways of stimulating apoptosis in neoplastic cells. Yet, there are difficulties in targeting this pathway: The ideal anti-cancer drug target is expressed only in cancer cells; however, IGF-1 and its receptor IGF-1R are ubiquitously expressed throughout the body. Moreover, when using antibodies against IGF-1R, the structurally similar insulin receptor might also be blocked, leading to hyperglycemia as a severe side effect. There are currently several phase I/II trials investigating IGF-1 and its receptor as a drug target in various kinds of cancer. Specifically, therapeutic effects on pancreatic cancer by combining a humanized monoclonal antibody against IGF-1R with other chemotherapeutics are being investigated. To improve the clinical outcome of mTOR inhibitors such as everolimus, it has been suggested to use combination therapies of mTOR inhibitors and IGF-1/IGF-1R inhibitors. In theory, this would counterbalance the feedback effects of mTOR inhibition on IGF-1 signaling. In conclusion, IGF-1 and its receptor are promising new drug targets in cancer therapy. Combination therapies of IGF-1/IGF-1R inhibitors and mTOR inhibitors could improve the clinical outcome.

Overview

Integrity signals

Registry

Crossref · 10.2174/187152011795677454

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 61 references

Cited by

See all 53

Metadata

Authors
Rieder, S., W. Michalski, C., Friess, H., & Kleeff, >.
Affiliations
Technical University of Munich (DE)
Venue
Anti-Cancer Agents in Medicinal Chemistry
Published
2011-06-01
Volume
11
Issue
5
Pages
427-433
ISSN
  • 1568-0118 (ISSN-L)
  • 1871-5206
OpenAlex
W2167677344
Cited by
50
References
61
Citations by year
2026: 1 · 2025: 4 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 6 · 2012: 2
FWCI
4.45
Type
journal article
Language
en
Open access
closed
Locations
  • Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
insulin-like growth factor I, IGF-1 receptor, pancreatic cancer, PI3K/Akt signaling, mTOR inhibition, everolimus, combination therapy, apoptosis, drug target specificity
MeSH terms
Humans, Insulin-Like Growth Factor I, Pancreatic Neoplasms, Signal Transduction, Receptor, IGF Type 1, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer. https://app.cochat.ai/papers/10.2174/187152011795677454
The paper
Rieder, S., W. Michalski, C., Friess, H., & Kleeff, >. (2011). Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer. Anti-Cancer Agents in Medicinal Chemistry. https://doi.org/10.2174/187152011795677454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.